Tracers / [225Ac]Ac-mcp-PEG8-Tz

[225Ac]Ac-mcp-PEG8-Tz

Also written as [Ac-225]Ac-mcp-PEG8-Tz

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Gynaecological cancer

What it is

Compound class: Tetrazine-macropa chelator conjugate (mcp-PEG8-Tz) for pretargeted radioimmunotherapy
Target / mechanism: Pretargeting via inverse-electron-demand Diels-Alder click reaction between tetrazine (Tz) on the chelator-radionuclide complex and trans-cyclooctene (TCO) conjugated to anti-MUC16 antibody AR9.6 PMID 39615062
Clinical application: Pretargeted alpha therapy for MUC16-positive high-grade serous ovarian cancer PMID 39615062
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	>97	—	mcp-PEG8-Tz	39615062 2025 Nucl Med Biol we used the mcp-PEG8-Tz precursor in Chelex-treated (Biorad; 142–2822) ammonium acetate buffer (pH 5.5, 0.25 M). The reaction mixture was agitated on a thermomixer for 5 min at 25 °C. — Radiolabeling of mcp-PEG8-Tz with 225Ac resulted in > 97% radiochemical conversion

Need this precursor?We can point you to suppliers for [225Ac]Ac-mcp-PEG8-Tz, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39615062. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39615062: 'mcp-PEG8-Tz precursor in Chelex-treated (Biorad; 142–2822) ammonium acetate buffer'.